Vantrexa · SCLC · United States · Oncology pharmacist · captured by James Whitfield on 26 May 2026 · reviewed by Dr. Marcus Lindqvist on 01 Jun 2026
Verbatim as captured; never edited
Oncology pharmacist at Memorial Sloan Kettering raised chemotherapy-free first line during a investigator meeting. They asked whether additional data would be presented at the next congress.
Human-approved by Dr. Marcus Lindqvist on 01 Jun 2026
Chemotherapy-free first line: request for data reported by oncology pharmacist (US).
helixor-private-llm-2026.05 · generated 26 May 2026, 10:00 UTC
AI summary
Chemotherapy-free first line raised by oncology pharmacist; aligns with Medical Affairs.
Source spans used by the model
Oncology pharmacist at Memorial Sloan Kettering raised chemotherapy-free first line during a investigator meeting. They asked whether additional data would be presented at the next congress.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Diagnosis and screening | Diagnosis and screening |
| Function | Medical Affairs | Medical Affairs |
| Priority | High | High |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 5 | 20% | 20.0 |
| Strategic alignment | 5 | 20% | 20.0 |
| Scientific importance | 1 | 15% | 3.0 |
| Urgency | 5 | 15% | 15.0 |
| Novelty | 1 | 10% | 2.0 |
| Actionability | 3 | 10% | 6.0 |
| Confidence | 5 | 5% | 5.0 |
| Breadth of occurrence | 2 | 5% | 2.0 |
| Total | High 73 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
24 May 2026 · Dr. Oscar Yamamoto, Memorial Sloan Kettering · MSL James Whitfield
Insight
Reviewed 01 Jun 2026 by Dr. Marcus Lindqvist
Action
Initiative
Decision
Outcome
Closure